drugset / Trial / NCT04021108
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
Phase 2
Active not recruiting
80 enrolled
Weill Medical College of Cornell University
Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized phase II study examining nivolumab alone versus radiation therapy with nivolumab in subjects who did not have disease progression to initial therapy with the combination of FOLFOX and Nivolumab.
Timeline
- Start
- 2019-07-22
- Primary completion
- 2025-06-11
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |